Skip to content
Peptide research

PT-141 (Bremelanotide)

Also known as Vyleesi
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

PT-141 (Bremelanotide) is a synthetic melanocortin agonist marketed off-label for low libido and ED. Evidence is strongest in women with HSDD, weaker for male ED, and speculative for appetite effects. Key risks include nausea in about 40%, potentially persistent focal skin hyperpigmentation, and transient blood-pressure increases. Uncontrolled hypertension and known cardiovascular disease are contraindications. It is FDA-approved only as a branded HSDD drug for women; compounded versions are subject to pharmacy and drug laws but are not FDA-approved or reviewed before marketing for safety, effectiveness and quality.

Read Full record

Studied uses & evidence

Studied uses(6)

  • HSDD treatment (women)

    High

    FDA-approved for HSDD, backed by two replicated 24-week phase 3 randomized placebo-controlled trials.

  • Erectile dysfunction (men)

    Medium

    Early controlled studies tested both intranasal and subcutaneous PT-141 in men; use in men remains off-label.

  • Sexual arousal (women)

    Medium

    Small randomized trials suggest an effect, but phase 3 trials targeted desire, not arousal.

Evidence limits

Evidence Level
Level 1 — FDA Approved

43 completed studies, ~3,500 participants. Two pivotal RECONNECT Phase 3 trials (n=1,247) + 52-week extension (n=684). Phase 2 in male ED. Phase 1 weight loss. Nausea 40%, flushing 20%, headache 11%. BP +6/3 mmHg transient.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Uncontrolled hypertension

    Absolute

    FDA label: causes transient blood pressure increases. Contraindicated in uncontrolled hypertension.

  • Cardiovascular disease

    High

    Known cardiovascular disease is an absolute contraindication in the FDA label. Patients at high cardiovascular risk are a separate group for whom use is not recommended.

General cautions

  • Pregnancy

    Absolute

    Pregnancy precaution: human data are insufficient, and animal studies indicate potential fetal harm. Use effective contraception and discontinue Vyleesi if pregnancy is suspected.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Nausea (40% of patients — manageable with antiemetics)

    High
  • Flushing (20%), headache (11%)

    Moderate
  • Transient blood pressure increase (~6/3 mmHg, peaks 2-4h, resolves 12h)

    Moderate
  • Focal skin hyperpigmentation (1% with labeled use, >33% with daily use, may be permanent)

    Moderate
  • Contraindicated: uncontrolled hypertension, cardiovascular disease

    High
  • Not recommended during pregnancy

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.